Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that its oral weight loss therapy medicine successfully completed its Phase 3 ...

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are ...

The investment bank said many companies faced thesis-changing Phase 3 readouts this year, with outcomes that could materially reshape valuations regardless of the broader macro backdrop. But UBS also ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

From the corporate jets of Teterboro Airport to the crowded halls of the J.P. Morgan Healthcare Conference, it’s a good time ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...